Skip to main content

Afeyan Noubar's Form 4 filing

Sana Biotechnology, Inc. (SANA) · filed Jun 8, 2023

Accession no.
0000899243-23-014953
Filed
Jun 8, 2023, 7:00 PM ET
Trade date
Jun 6-7, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $2.53M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Afeyan NoubarCIK 000122201210% Owner
Flagship Ventures Fund V, L.P.CIK 000162763910% Owner
Flagship Ventures Fund V General Partner LLCCIK 000172457510% Owner
Flagship V VentureLabs Rx Fund, L.P.CIK 000172493910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 6, 2023Common StockSSaleDisposed−181,461$6.31−$1,144,311.2110,920,533Indirect
Jun 6, 2023Common StockSSaleDisposed−22,297$6.31−$140,607.111,403,037Indirect
Jun 7, 2023Common StockSSaleDisposed−177,240$6.24−$1,105,924.4310,743,293Indirect
Jun 7, 2023Common StockSSaleDisposed−22,760$6.24−$142,015.571,380,277Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)